阿玛琳 AMRN 深 沪
等待开盘 09-14 09:30:00 美东时间
13.80
-0.240
-1.71%
华盛通- 最 高14.10
- 今 开14.09
- 成交量 4.94万股
- 最 低 13.68
- 昨 收 14.04
- 总市值 2.91亿
- 52周最高 20.90
- 市盈率 静 --
- 换手率 0.23%
- 52周最低 12.96
- 委 比 -84.25%
- 总股本 2112.28万
- 历史最高 522.40
- 量 比 0.79
- 振 幅 2.99%
- 历史最低 7.08
- 每 手 1
- 风险率 1.43%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 罗斯百货、迪尔股份获多家大行上调目标价；沃尔玛、Advance遭多家大行下调目标价
今日重点评级关注：摩根士丹利：维持Ultragenyx Pharmaceutical"超配"评级，目标价从67美元升至74美元；Truist Securities：维持Solid Biosciences"买入"评级，目标价从16美元升至20美元
08-24 16:40
JP Morgan Reinstates Underweight on Amarin Corp, Announces $13 Price Target
JP Morgan analyst Jessica Fye reinstates Amarin Corp (NASDAQ:AMRN) with a Underweight and announces $13 price target.
08-22 03:10
Amarin Corp Q2 Sales $42.211M Miss $44.550M Estimate
Amarin Corp (NASDAQ:AMRN) reported quarterly sales of $42.211 million which missed the analyst consensus estimate of $44.550 million by 5.25 percent. This is a 41.97 percent decrease over sales of $72.740 million the same period last year.
07-29 19:04
Amarin Highlights Recent FDA Approval Of Injectable Apolipoprotein C-III Therapies For Treatment Of Severe Hypertriglyceridemia, Defined As Triglycerides Greater Than Or Equal To 500 mg/dL
Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, applauds the recent FDA approval of injectable apolipoprotein C-III (APOC3) therapies for the treatment of severe hypertriglyceridemia (sHTG), defined as triglycerides (TG) greater...
07-01 04:18
U.S. Supreme Court Rules In Favor Of Hikma Pharmaceuticals V Amarin Pharmaceuticals Over Patent Infringement Claims By Amarin
https://www.supremecourt.gov/opinions/25pdf/24-889_5i36.pdf
06-04 22:10
Amarin Announces New Data From A Post Hoc Analysis Of The REDUCE-IT Trial; Apolipoprotein B More Effectively Identified Individuals At Increased Residual Cardiovascular Risk
Amarin Corporation plc (NASDAQ:AMRN) (Amarin), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today announced new data from a post hoc analysis of the REDUCE-IT® trial
05-27 20:03
Earnings Scheduled For April 29, 2026
Companies Reporting Before The Bell • Extreme Networks (NASDAQ:EXTR) is likely ...
04-29 19:11
Amarin Corp Q1 Sales $45.132M Beat $43.771M Estimate
Amarin Corp (NASDAQ:AMRN) reported quarterly sales of $45.132 million which beat the analyst consensus estimate of $43.771 million by 3.11 percent. This is a 7.41 percent increase over sales of $42.017 million the same
04-29 19:04
Amarin Highlights 2026 ACC/AHA Dyslipidemia Guideline Emphasizing CV Risk Management In Hypertriglyceridemia
Amarin Corporation plc (NASDAQ:AMRN) ("Amarin"), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, applauded the recommendation that the treatment of CV risk in patients with
03-18 20:33
Amarin shares are trading lower after the company reported a Q4 sales miss.
Amarin shares are trading lower after the company reported a Q4 sales miss.
02-26 01:24
